Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Lilly (LLY) says solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease in latest study

J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data

March 9, 2023 1:01 PM EST

J.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of the upcoming release of the donanemab ph3 data.

Analyst Chris Schott wrote in a note, Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as... More